Celyad SA

Back to All Transactions

Celyad SA
For more information regarding this transaction contact:
  • Dave McDonald Investment Banking 612.326.1268
  • Rob Martin Investment Banking 612.260.5850

Lake Street is pleased to announce it served as co-managing underwriter for Celyad SA (NASDAQ: CYAD), a clinical stage biopharmaceutical company, in its global offering totaling $100.1 million in gross proceeds. Included in the offering were 1,460,000 new ordinary shares, consisting of 1,168,000 American Depository Shares (“ADSs”) at $68.56 per ADS, and 292,000 ordinary shares at a price of EUR 60.25 per share. The shares were placed in a concurrent public offering in the United States and private placement in Europe.

About Celyad SA

Based in Belgium, Celyad is a leader in engineered cell therapies with clinical programs initially targeting indications in cardiology and oncology. Celyad is developing its lead cardiovascular disease product candidate, C-Cure®, for the treatment of ischemic heart failure, and has completed enrollment of a Phase III trial in Europe and Israel. In addition, the Company is developing a novel portfolio of CAR T-cell therapies that utilize human Natural Killer cell receptors for the treatment of numerous blood and solid cancers. Its lead oncology product candidate, NKG2D CAR T-cell, entered a Phase I clinical trial in April 2015. 


Mike Townley
Head of Investment Banking


Email Mike

Dave McDonald
Head of Life Science Investment Banking


Email Dave


Tim Klein

Investment Banking


Email Tim


Rob Martin

Investment Banking


Email Rob


Steve Rickman

Investment Banking


Email Steve